A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 24 weeks and BI 201335 240 mg for 12 weeks in combination with pegylated interferon-α and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C infection